Phanes Therapeutics Inc, a US-based company that deals with innovative discovery research in immuno-oncology, announced on Tuesday that it has named Paul Chu, MBA, as its vice president of Business Development.
Chu has held senior leadership roles in both small biotech companies and large multi-national corporations. He has served as vice president of Business Development at HUYABIO International. He has held similar roles at AiViva BioPharma and UroGen Pharma and earlier in his career was director of Business Development at Allergan, Inc. where he spearheaded multiple M&A transactions.
Dr Ming Wang, founder and CEO, said, 'We welcome Paul to the Phanes family and are delighted to appoint a professional of his calibre as vice president of Business Development. We have built a strong pipeline in immuno-oncology by leveraging our proprietary technology platforms and expect to file 3 INDs in 2022, including one best-in-class monoclonal antibody (mAb) program and two first-in-class bispecific antibody programs. We look forward to benefitting from Paul's extensive experience and network in Oncology as we enter 2022, which we expect to be a transformational year for Phanes.'
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval